Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Aspergillosis Clear all
Terminated Phase 2 Interventional Results available

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

NCT04240886
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
fosmanogepix
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Duarte, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

A Multicenter, Prospective, Randomized, Double-Blind Clinical Trial Comparing Itraconazole Oral Solution in Cyclodextrin to Placebo in the Treatment of Aspergilloma

NCT00005668
View directory record Official record
Conditions
Aspergillosis, Lung Diseases, Fungal
Interventions
Itraconazole oral solution
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

NCT05707156
View directory record Official record
Conditions
Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of PC945 (Opelconazole) in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis (OPERA-T Study)

NCT05238116
View directory record Official record
Conditions
Refractory IPA
Interventions
PC945, Placebo
Drug
Lead sponsor
Pulmocide Ltd
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Recruiting No phase listed Observational

Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections

NCT03827694
View directory record Official record
Conditions
Pulmonary Invasive Fungal Infections, Pulmonary Invasive Aspergillosis
Interventions
Non-Invasive Testing for PIFI
Diagnostic Test
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
120 Days to 21 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
32
States / cities
Little Rock, Arkansas • La Jolla, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Not applicable Interventional Results available

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

NCT01222273
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
cholecalciferol (Vitamin D3)
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

NCT04442269
View directory record Official record
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)

NCT04818853
View directory record Official record
Conditions
Covid19, Aspergillosis, Fungal Infection
Interventions
Observation to monitor patients for these infections
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

NCT02879305
View directory record Official record
Conditions
Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions
Daprodustat, rhEPO, Placebo, Iron therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
2,964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
126
States / cities
Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Voriconazole Prophylaxis Against Aspergillosis in Lung Transplant Recipients

NCT00177827
View directory record Official record
Conditions
Post Lung Transplantation
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

NCT03327727
View directory record Official record
Conditions
Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions
Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B
Drug
Lead sponsor
Vical
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
11
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

NCT05037851
View directory record Official record
Conditions
Pulmonary Aspergillosis
Interventions
Opelconazole, Standard of Care
Drug
Lead sponsor
Pulmocide Ltd
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis

NCT03960606
View directory record Official record
Conditions
Allergic Bronchopulmonary Aspergillosis
Interventions
PUR1900, Placebo
Combination Product
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Denver, Colorado • New Haven, Connecticut • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects

NCT00940017
View directory record Official record
Conditions
Aspergillosis, Candidemia
Interventions
anidulafungin and voriconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 8, 2010 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992
View directory record Official record
Conditions
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions
Ibrexafungerp
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Immune Profiles in CF Fungal Infection

NCT04476758
View directory record Official record
Conditions
Cystic Fibrosis, Fungal Infection, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
8 Years to 25 Years
Enrollment
24 participants
Timeline
2021 – 2023
U.S. locations
1
States / cities
Highlands Ranch, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Mucormycosis in COVID-19

NCT04935463
View directory record Official record
Conditions
Covid19, Mucormycosis, Aspergillosis, Candida Infection
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Not listed
Enrollment
728 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mechanisms of Immune Tolerance and Inflammation in Patients With Cystic Fibrosis With ABPA

NCT00585364
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years and older
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis

NCT03672292
View directory record Official record
Conditions
Invasive Pulmonary Aspergillosis
Interventions
SCY-078, Voriconazole, Oral Placebo Tablets
Drug · Other
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

NCT05667662
View directory record Official record
Conditions
ABPA
Interventions
Itraconazole Powder, Placebo
Drug
Lead sponsor
Pulmatrix Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 3 Interventional

Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis

NCT00003031
View directory record Official record
Conditions
Infection, Pulmonary Complications
Interventions
amphotericin B deoxycholate, voriconazole
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
12 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Wethersfield, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2012 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis

NCT00923832
View directory record Official record
Conditions
Immunocompromised Host, Invasive Pulmonary Fungal Infection, Invasive Pulmonary Aspergillosis, Invasive Pulmonary Zygomycosis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 23, 2026, 8:14 PM EDT
Withdrawn Phase 4 Interventional

Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

NCT04108962
View directory record Official record
Conditions
ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis
Interventions
Fasenra, 30 Mg/mL Subcutaneous Solution
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 23, 2026, 8:14 PM EDT